UNSPSC 51282205: Cefmetazole sodium

This classification denotes a cephalosporin antibiotic with the molecular formula C15H16N7O5S3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 37Y9VR4W7A, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((((cyanomethyl)thio)acetyl)amino)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, (6r-cis)- but more generally known as cefmetazole sodium, which bears US NIH Compound Identifier 42008.

UNSPSC 51282205 Cefmetazole sodium is a Commodity code that does not match the work actually being solicited by state and local government buyers under this identifier. The recent opportunities tagged to this code address naloxone procurement, fire department medical and first aid supplies, generic pharmaceutical distribution through cooperative purchasing, and a Request for Information on direct-to-manufacturer prescription programs — none of which involve cefmetazole sodium or other specific injectable antibiotics. State and local issuing bodies are acquiring broad medical supplies, emergency-response consumables, and pharmacy benefit management services, not the narrow antibiotic product the code nominally describes. This mismatch suggests either a data-classification error in the state procurement systems recording these opportunities or a code that sees minimal relevant recent activity.

The issuing-body mix includes city fire departments (City of Tampa), county health systems (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota MMCAP with Oregon participation). The geographic spread captures Florida, Texas, Minnesota, and Oregon in the most recent cycle. Representative opportunities include the City of Tampa's IFB 26P00145 for medical and first aid supplies due March 13, 2026, estimated at $700,000 and sheltered for certified Small Local Business Enterprises; Seminole County's IFB 60459723LAS for naloxone and drug deactivation systems posted June 30, 2026 with a July 26 response deadline; the Minnesota MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products due March 26, 2026; and the Texas HHS Commission's RFI HHS0017013 on direct-to-manufacturer prescriptions posted April 3, 2026. Bidders pursuing these opportunities should verify the actual commodity codes with issuing bodies before investment, as the code classification does not reliably predict procurement activity.